Gentium Begins Trading on NASDAQ; New Ticker Symbol: GENT

Gentium S.p.A. (NASDAQ:GENT)(AMEX:GNT) (the Company)
today announced that its American Depository Shares (ADSs) will be
listed and begin trading today on the NASDAQ National Market System
under the symbol: GENT. Gentium ADSs will no longer be listed on the
American Stock Exchange.
   The NASDAQ Stock Market is the largest electronic screen-based
equity securities market in the United States with approximately 3,200
listed companies. It is a highly-regulated electronic securities
market comprised of competing market makers whose trading is supported
by a communications network linking them to quotation dissemination,
trade reporting, and order execution systems. The NASDAQ Stock Market,
which includes the NASDAQ NMS and the NASDAQ Capital Market, is
operated by the NASDAQ Stock Market, Inc.

   About Gentium

   Gentium S.p.A. is a biopharmaceutical company located in Villa
Guardia (Como), Italy that is focused on the research, discovery and
development of drugs derived from DNA extracted from natural sources,
and drugs that are synthetic derivatives, to treat and prevent a
variety of vascular diseases and conditions related to cancer and
cancer treatments. Defibrotide, the Company's lead product candidate
in the U.S., is an investigational drug that has been granted Orphan
Drug status by the U.S. FDA to treat Severe VOD and Fast Track
designation for the treatment of Severe VOD in recipients of stem cell
transplants.

   Cautionary Note Regarding Forward-Looking Statements

   This press release contains "forward-looking statements." In some
cases, you can identify these statements by forward-looking words such
as "may," "might," "will," "should," "expect," "plan," "anticipate,"
"believe," "estimate," "predict," "potential" or "continue," the
negative of these terms and other comparable terminology. These
statements are not historical facts but instead represent the
Company's belief regarding future results, many of which, by their
nature, are inherently uncertain and outside the Company's control. It
is possible that actual results may differ, possibly materially, from
those anticipated in these forward-looking statements. For a
discussion of some of the risks and important factors that could
affect future results, see the discussion in our Prospectus filed with
the Securities and Exchange Commission under Rule 424(b)(5) under the
caption "Risk Factors."

   Source: Gentium